Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;55(10):3130-3134.
doi: 10.1128/JCM.00788-17. Epub 2017 Aug 9.

Determination of Disk Diffusion and MIC Quality Control Guidelines for High-Dose Cefepime-Tazobactam (WCK 4282), a Novel Antibacterial Combination Consisting of a β-Lactamase Inhibitor and a Fourth-Generation Cephalosporin

Stefan Riedel  1 , Michael D Huband  2 , Helio S Sader  3 , Robert K Flamm  3 , Ronald N Jones  3
Affiliations

Determination of Disk Diffusion and MIC Quality Control Guidelines for High-Dose Cefepime-Tazobactam (WCK 4282), a Novel Antibacterial Combination Consisting of a β-Lactamase Inhibitor and a Fourth-Generation Cephalosporin

Stefan Riedel et al. J Clin Microbiol. 2017 Oct.

Abstract

High-dose cefepime-tazobactam (1:1; WCK 4282), a novel antibacterial combination consisting of the β-lactamase inhibitor tazobactam and a fourth-generation cephalosporin, is under clinical development for the treatment of serious Gram-negative infections. A quality control (QC) study was performed to establish disk diffusion and MIC ranges for cefepime-tazobactam for multiple QC reference strains. The cefepime-tazobactam QC ranges for a fixed tazobactam MIC of 8 μg/ml and disk diffusion (30/20-μg disk) test methods were approved by the CLSI Subcommittee on Antimicrobial Susceptibility Testing in January 2015 and January 2016. These QC ranges will be important for accurate in vitro activity evaluations of cefepime-tazobactam when tested against clinical Gram-negative bacteria during clinical studies and routine patient care.

Keywords: WCK 4282; cefepime-tazobactam; quality control.

PubMed Disclaimer

References

    1. Bush K, Bradford PA. 2016. Beta-lactams and beta-lactamase inhibitors: an overview. Cold Spring Harb Perspect Med 6:a025247. doi:10.1101/cshperspect.a025247. - DOI - PMC - PubMed
    1. Thomson JM, Bonomo RA. 2005. The threat of antibiotic resistance in Gram-negative pathogenic bacteria: beta-lactams in peril! Curr Opin Microbiol 8:518–524. - PubMed
    1. Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya O, Miller JH, Mobashery S, Piddock LJ, Projan S, Thomas CM, Tomasz A, Tulkens PM, Walsh TR, Watson JD, Witkowski J, Witte W, Wright G, Yeh P, Zgurskaya HI. 2011. Tackling antibiotic resistance. Nat Rev Microbiol 9:894–896. doi:10.1038/nrmicro2693. - DOI - PMC - PubMed
    1. Sader HS, Castanheira M, Mendes RE, Flamm RK, Jones RN. 2017. Antimicrobial activity of high-proportion cefepime-tazobactam (WCK 4282) against a large number of Gram-negative isolates collected worldwide in 2014. Antimicrob Agents Chemother 61:e02409-16. doi:10.1128/AAC.02409-16. - DOI - PMC - PubMed
    1. Clinical and Laboratory Standards Institute. 2016. Development of in vitro susceptibility testing criteria and quality control parameters—4th ed. CLSI guideline M23-A4 Clinical and Laboratory Standards Institute, Wayne, PA.

MeSH terms

LinkOut - more resources